197 related articles for article (PubMed ID: 32841554)
1. Beyond 52-Week Long-Term Safety: Long-Term Outcomes of Aripiprazole Lauroxil for Patients With Schizophrenia Continuing in an Extension Study.
Lauriello J; Claxton A; Du Y; Weiden PJ
J Clin Psychiatry; 2020 Aug; 81(5):. PubMed ID: 32841554
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of a 2-Month Formulation of Aripiprazole Lauroxil With 1-Day Initiation in Patients Hospitalized for Acute Schizophrenia Transitioned to Outpatient Care: Phase 3, Randomized, Double-Blind, Active-Control ALPINE Study.
Weiden PJ; Claxton A; Kunovac J; Walling DP; Du Y; Yao B; Yagoda S; Bidollari I; Keane E; Cash E
J Clin Psychiatry; 2020 May; 81(3):. PubMed ID: 32433835
[TBL] [Abstract][Full Text] [Related]
3. Durability of Therapeutic Response With Long-Term Aripiprazole Lauroxil Treatment Following Successful Resolution of an Acute Episode of Schizophrenia.
McEvoy JP; Risinger R; Mykhnyak S; Du Y; Liu CC; Stanford AD; Weiden PJ
J Clin Psychiatry; 2017; 78(8):1103-1109. PubMed ID: 28937706
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia.
Nasrallah HA; Aquila R; Du Y; Stanford AD; Claxton A; Weiden PJ
CNS Spectr; 2019 Aug; 24(4):395-403. PubMed ID: 30109845
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia.
Meltzer HY; Risinger R; Nasrallah HA; Du Y; Zummo J; Corey L; Bose A; Stankovic S; Silverman BL; Ehrich EW
J Clin Psychiatry; 2015 Aug; 76(8):1085-90. PubMed ID: 26114240
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study.
Weiden PJ; Du Y; von Moltke L; Wehr A; Hard M; Marandi M; Walling DP
CNS Drugs; 2020 Sep; 34(9):961-972. PubMed ID: 32621071
[TBL] [Abstract][Full Text] [Related]
7. Safety and Tolerability of Starting Aripiprazole Lauroxil With Aripiprazole Lauroxil NanoCrystal Dispersion in 1 Day Followed by Aripiprazole Lauroxil Every 2 Months Using Paliperidone Palmitate Monthly as an Active Control in Patients With Schizophrenia: A Post Hoc Analysis of a Randomized Controlled Trial.
Citrome L; Yagoda S; Bidollari I; Wang M
J Clin Psychiatry; 2024 Feb; 85(1):. PubMed ID: 38416865
[No Abstract] [Full Text] [Related]
8. Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the Positive and Negative Syndrome Scale-supportive analyses from a Phase 3 study.
Citrome L; Risinger R; Cutler AJ; Du Y; Zummo J; Nasrallah HA; Silverman BL
CNS Spectr; 2018 Aug; 23(4):284-290. PubMed ID: 28625204
[TBL] [Abstract][Full Text] [Related]
9. Switching stable patients with schizophrenia from their oral antipsychotics to aripiprazole lauroxil: a post hoc safety analysis of the initial 12-week crossover period.
Weiden PJ; Du Y; Liu CC; Stanford AD
CNS Spectr; 2019 Aug; 24(4):419-425. PubMed ID: 29941057
[TBL] [Abstract][Full Text] [Related]
10. A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil.
Risinger R; Hard M; Weiden PJ
Psychopharmacol Bull; 2017 Aug; 47(3):26-34. PubMed ID: 28839337
[TBL] [Abstract][Full Text] [Related]
11. Long-term effect of aripiprazole lauroxil on health-related quality of life in patients with schizophrenia.
McEvoy JP; Weiden PJ; Lysaker PH; Sun X; O'Sullivan AK
BMC Psychiatry; 2021 Mar; 21(1):164. PubMed ID: 33761928
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of aripiprazole lauroxil in schizophrenic patients presenting with severe psychotic symptoms during an acute exacerbation.
Potkin SG; Risinger R; Du Y; Zummo J; Bose A; Silverman B; Stankovic S; Ehrich E
Schizophr Res; 2017 Dec; 190():115-120. PubMed ID: 28342578
[TBL] [Abstract][Full Text] [Related]
13. Aripiprazole lauroxil 2-month formulation with 1-day initiation in patients hospitalized for an acute exacerbation of schizophrenia: exploratory efficacy and patient-reported outcomes in the randomized controlled ALPINE study.
Nasrallah HA; Weiden PJ; Walling DP; Du Y; Yao B; Yagoda S; Claxton A
BMC Psychiatry; 2021 Oct; 21(1):492. PubMed ID: 34625041
[TBL] [Abstract][Full Text] [Related]
14. Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil.
Citrome L
Expert Rev Clin Pharmacol; 2016; 9(2):169-86. PubMed ID: 26573020
[TBL] [Abstract][Full Text] [Related]
15. Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles and Related Safety Considerations Among Patients With Acute Schizophrenia.
Nasrallah HA; Newcomer JW; Risinger R; Du Y; Zummo J; Bose A; Stankovic S; Silverman BL; Ehrich EW
J Clin Psychiatry; 2016 Nov; 77(11):1519-1525. PubMed ID: 27574838
[TBL] [Abstract][Full Text] [Related]
16. Aripiprazole Lauroxil Compared with Paliperidone Palmitate in Patients with Schizophrenia: An Indirect Treatment Comparison.
Cameron C; Zummo J; Desai DN; Drake C; Hutton B; Kotb A; Weiden PJ
Value Health; 2017; 20(7):876-885. PubMed ID: 28712616
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study.
Savitz AJ; Lane R; Nuamah I; Gopal S; Hough D
J Am Acad Child Adolesc Psychiatry; 2015 Feb; 54(2):126-137.e1. PubMed ID: 25617253
[TBL] [Abstract][Full Text] [Related]
18. Social and functional outcomes with two doses of aripiprazole lauroxil vs placebo in patients with schizophrenia: a post-hoc analysis of a 12-week phase 3 efficacy study.
Correll CU; Stanford AD; Claxton A; Du Y; Weiden PJ
Psychiatry Res; 2019 Apr; 274():176-181. PubMed ID: 30802689
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
Kane JM; Carson WH; Saha AR; McQuade RD; Ingenito GG; Zimbroff DL; Ali MW
J Clin Psychiatry; 2002 Sep; 63(9):763-71. PubMed ID: 12363115
[TBL] [Abstract][Full Text] [Related]
20. Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia.
Citrome L; Du Y; Risinger R; Stankovic S; Claxton A; Zummo J; Bose A; Silverman BL; Ehrich EW
Int Clin Psychopharmacol; 2016 Mar; 31(2):69-75. PubMed ID: 26517202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]